Skip to Main Content

Paper Details

Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Ann Clin Transl Neurol
1
2023
Author NameAffiliation
Friedemann PaulExperimental and Clinical Research Center, Max Delbruck Center for Molecular Medicine and Charite, Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat zu Berlin
Bruce A C CreeUCSF Weill Institute for Neurosciences, University of California San Francisco
  • 1 - 2

Datasets

Release 1.2